Drug intelligence / Profile preview

Cozisol

Development stage: Unknown
Lead developer: Bio-Technology General
Administration: Topical

Overview

Cozisol is a commercial-stage asset that was part of BTG plc's portfolio, a UK-based specialty pharmaceutical and biotechnology company. It was acquired by Boston Scientific in 2019 as part of a larger acquisition aimed at expanding Boston Scientific's capabilities in interventional medicine, particularly in high-growth areas like interventional oncology and vascular embolization. While BTG's portfolio included specialty pharmaceuticals and devices, specific details regarding Cozisol's mechanism of action, primary indication, or modality are not available in the provided information.

Beyond the preview

Go deeper on Cozisol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cozisol.

Explore the full profile